34

nanotimes

Companies Facts

of LEDs disperses light more evenly and effectively across the screen, creating pictures that are clearer, smoother and more refined. What’s more, an Anti- Reflection Panel on the LEX8 screen minimizes reflection from an external light source – including – ensuring the picture always stays crystal clear.

The LEX8 boasts improved localized dimming in both 2D and 3D with its Micro Pixel Control. By mani- pulating individual LED blocks, Micro Pixel Control adds even greater range and life to colors, from the deepest, darkest blacks to the most natural colors. The LEX8 is further enhanced by LG’s TruMotion 400Hz, which delivers super-fast processing rate for moving images making them virtually blur-free. The overall effect is a picture so smooth, sharp and realis- tic, it’s as if the action is playing out right in viewers’ living rooms.

“In creating our first television using nano techno- logy, LG is continuing to set new standards in TV technology and demonstrating once again that we’re pushing the envelope of home entertainment,” said Simon Kang, President and CEO of LG Home En- tertainment Company. “Just as difficult as it is to watch standard TV after experiencing high definition, people will resist going back to regular LED LCD TVs after viewing the LEX8.”

Thanks to NANO Lighting Technology and FULL LED Panel, the LEX8 is still only 0.88cm thick with a bezel just 1.25cm wide, indisputably the slimmest and nar- rowest of any FULL LED TV in the world. http://www.lg.com

L

ife Technologies Corporation (NASDAQ: LIFE) has finalized cell line license agreements with a

number of companies to provide rights to Life Tech- nologies’ proprietary CHO (Chinese hamster ovary) cell lines for the production of recombinant proteins used as therapeutic agents and vaccines. New licensees include Advanced BioScience Labo- ratories, Inc., CNA Development L.L.C., Chong Kun Dang Pharmaceutical Corporation and DiNonA Inc. of Korea, RecipharmCobra Biologics, Ltd. of the United Kingdom, evitria SA of Switzerland, Fu- sion Antibodies of Northern Ireland, Indian Immu- nologicals Limited of Hyderabad, India and others. Commercial use rights have additionally been offered to many of the hundreds of institutions already using Life Technologies’ proprietary cell lines for research and development. http://www.lifetechnologies.com

M

agForce Nanotechnologies AG (FSE: MF6) an- nounced the publication of clinical data from

a clinical study examining the safety and efficacy of intratumoral thermotherapy using magnetic iron- oxide nanoparticles combined with external beam radiotherapy in patients with recurrent glioblastoma multiforme. “This data publication provides detailed insight into the clinical data that supported our recent regula- tory approval for Nano-Cancer®

therapy. Through

the publication, we are pleased to address a wider international audience and give them insight into MagForce‘s novel concept of using nanotechnology for the treatment of cancer,” said Dr. Peter Heinrich, CEO of MagForce Nanotechnologies AG. “We are currently focused on strengthening our commerciali- zation team and infrastructures in preparation for the next strategic steps, including the planned Q1 2011 product launch in Germany, additional clinical trials, and further internationalization.”

10-09 :: September 2010